- Previous Close
43.76 - Open
0.00 - Bid 42.48 x --
- Ask 42.80 x --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 44.95 - Volume
0 - Avg. Volume
43 - Market Cap (intraday)
117.91B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-2.14 - Earnings Date Nov 7, 2024 - Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
www.beigene.comRecent News: B1GN34.SA
View MorePerformance Overview: B1GN34.SA
Trailing total returns as of 9/4/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B1GN34.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B1GN34.SA
View MoreValuation Measures
Market Cap
117.91B
Enterprise Value
109.47B
Trailing P/E
--
Forward P/E
200.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.41
Price/Book (mrq)
3.19
Enterprise Value/Revenue
6.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.91%
Return on Assets (ttm)
-9.69%
Return on Equity (ttm)
-14.62%
Revenue (ttm)
3.1B
Net Income Avi to Common (ttm)
-523.7M
Diluted EPS (ttm)
-2.14
Balance Sheet and Cash Flow
Total Cash (mrq)
2.59B
Total Debt/Equity (mrq)
32.38%
Levered Free Cash Flow (ttm)
-957.16M